HCPLive 5 Stories in Under 5: Week of 03/08

About this episode

A recap of the top 5 healthcare stories from the past week in under 5 minutes.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive ! RAINIER: Povetacicept Reduces Proteinuria By 52.0% A pre-specified week 36 interim analysis of the phase 3 RAINIER trial found that povetacicept, a dual BAFF/APRIL inhibitor, reduced proteinuria by 52% from baseline and achieved a statistically significant 49.8% reduction in UPCR versus placebo in patients with IgA nephropathy. Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA Trial The FDA accepted Mineralys Therapeutics' NDA for lorundrostat as an add-on treatment for hypertension, supported by phase 3 and phase 2 trial data, with a PDUFA action date set for December 22, 2026. Discontinuing GLP-1 Treatment Associated With Up to 60% Weight Regain, With Brajan Budini New findings indicate that stopping GLP-1 receptor agonist therapy leads to a predictable pattern of weight regain—reaching approximately 60% at…

Topics covered

• healthcare
• clinical updates
• IgA nephropathy
• hypertension
• FDA approvals

Keywords

• povetacicept
• lorundrostat
• proteinuria
• FDA NDA
• clinical trials

Mentioned in this episode

Products: RAINIER, lorundrostat, povetacicept

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min